Item 5.07 Submission of Matters to a Vote of Security Holders.
Amylyx Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 6, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2024. The final voting results are set forth below.
Proposal 1 – Election of Class III Directors
The stockholders of the Company elected Joshua Cohen and Daphne Quimi as Class III directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2027 or until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:
|
|
|
|
|
|
|
| Name |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
| Joshua Cohen |
|
32,649,858 |
|
11,308,745 |
|
8,341,537 |
| Daphne Quimi |
|
32,463,982 |
|
11,494,621 |
|
8,341,537 |
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the stockholders’ vote with respect to such ratification were as follows:
|
|
|
|
|
|
|
| Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
| 52,023,591 |
|
162,947 |
|
113,602 |
|
0 |
Proposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company’s Named Executive Officers
The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (“NEOs”). The results of the stockholders’ vote with respect to such approval were as follows:
|
|
|
|
|
|
|
| Votes For |
|
Votes Against |
|
Abstain |
|
Broker Non-Votes |
| 41,211,831 |
|
2,708,178 |
|
38,594 |
|
8,341,537 |
Proposal 4 – Non-Binding, Advisory Vote on the Preferred Frequency of Future Advisory Votes on the Compensation of the Company’s Named Executive Officers
The stockholders of the Company voted, on a non-binding, advisory basis, for “One Year” as the preferred frequency of future advisory votes on the compensation of the Company’s NEOs. In light of the results of the advisory vote, the Company will continue to hold an advisory say-on-pay vote annually until the next stockholder vote on the frequency of future advisory votes to approve executive compensation. The results of the stockholders’ vote with respect to such approval were as follows:
|
|
|
|
|
|
|
|
|
| One Year |
|
Two Years |
|
Three Years |
|
Abstain |
|
Broker Non-Votes |
| 38,275,989 |
|
22,388 |
|
5,612,768 |
|
47,458 |
|
8,341,537 |
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.